Two characteristics of tau PET position it as a useful tool for staging AD: (1) it closely predicts neurodegeneration and cognitive impairment; (2) it differentiates individuals with AD and MCI due to AD from those with normal cognition, as demonstrated in Figure 1 [33]. Here, MAPT is linked to Cognitive impairment.